Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program
Pfizer Inc and Ionis Pharmaceuticals, Inc announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).